Nuclear Export Inhibition for Pancreatic Cancer Therapy

Curcumin and dietary polyphenol research: beyond drug discovery

(2018) Tian-ru Jin   ACTA PHARMACOLOGICA SINICA

NoLogo: a new statistical model highlights the diversity and suggests new classes of Crm1-dependent nuclear export signals

(2018) Muluye E. Liku et al.   BMC BIOINFORMATICS

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Karyopherins in cancer

(2018) Tolga Çağatay et al.   CURRENT OPINION IN CELL BIOLOGY

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia

(2018) Amy Y. Wang et al.   Journal of Hematology & Oncology

Selinexor and dexamethasone in multiple myeloma

(2018) Talha Khan Burki   LANCET ONCOLOGY

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer

(2018) Xiao X. Wei et al.   ONCOLOGIST

Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment

(2018) Daniel Ansari et al.   Oncotarget

Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy

(2018) Neus Martinez-Bosch et al.   Cancers

Expression of exportin 1 (XPO1/CRM1) in pancreatic adenocarcinoma.

(2017) David M Saulino et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer

(2017) Arjun Gupta et al.   Journal of Thoracic Oncology

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration

(2017) Asfar S. Azmi et al.   Oncotarget

XPO1 target occupancy measurements confirm the selinexor recommended phase 2 dose

(2017) Marsha L. Crochiere et al.   Oncotarget

Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3

(2017) Young Hwa Soung et al.   Oncotarget

The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase

(2016) Sabrina Crivellaro et al.   BMC CANCER

Abstract B38: Clinical translation of nuclear export inhibitor in metastatic pancreatic cancer

(2016) Asfar S. Azmi et al.   CANCER RESEARCH

Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer

(2016) Ying Chen et al.   CLINICAL CANCER RESEARCH

The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia

(2016) Thomas Vercruysse et al.   CLINICAL CANCER RESEARCH

Perforating the nuclear boundary – how nuclear pore complexes assemble

(2016) Marion Weberruss et al.   JOURNAL OF CELL SCIENCE

Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia

(2016) Thomas B. Alexander et al.   JOURNAL OF CLINICAL ONCOLOGY

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

(2016) Albiruni R. Abdul Razak et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

(2016) Mrinal M. Gounder et al.   JOURNAL OF CLINICAL ONCOLOGY

Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies

(2016) Z A Hing et al.   LEUKEMIA

Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor

(2016) Tingyu Wu et al.   MOLECULAR CANCER THERAPEUTICS

Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export

(2016) Jasper Edgar Neggers et al.   Oncotarget

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma

(2016) Robert Nakayama et al.   Oncotarget

The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma

(2016) Maria Diab et al.   Journal of Clinical Medicine

Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells

(2015) Mingshan Niu et al.   CANCER BIOLOGY & THERAPY

Identifying Drug-Target Selectivity of Small-Molecule CRM1/XPO1 Inhibitors by CRISPR/Cas9 Genome Editing

(2015) Jasper E. Neggers et al.   CHEMISTRY & BIOLOGY

XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer

(2015) I. Ferreiro-Neira et al.   CLINICAL CANCER RESEARCH

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer

(2015) S. Kazim et al.   MOLECULAR CANCER THERAPEUTICS

Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer

(2015) Xuejiao Liu et al.   Journal of Ovarian Research

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition

(2015) Asfar S. Azmi et al.   Scientific Reports

RNA Export through the NPC in Eukaryotes

(2015) Masumi Okamura et al.   Genes

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer

(2015) Jiankun Gao et al.   Oncotarget

KPT-330 has antitumour activity against non-small cell lung cancer

(2014) H Sun et al.   BRITISH JOURNAL OF CANCER

SINE (selective inhibitor of nuclear export) – translational science in a new class of anti-cancer agents

(2014) John Gerecitano   Journal of Hematology & Oncology

XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)

(2014) Giovanni Gravina et al.   Journal of Hematology & Oncology

CRM1 Is a Direct Cellular Target of the Natural Anti-cancer Agent Plumbagin

(2014) Xuejiao Liu et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells

(2014) Y Zhong et al.   LEUKEMIA

XPO1 (CRM1) Inhibition Represses STAT3 Activation to Drive a Survivin-Dependent Oncogenic Switch in Triple-Negative Breast Cancer

(2014) Y. Cheng et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma

(2014) Adam L. Green et al.   NEURO-ONCOLOGY

Specific Inhibition of the Nuclear Exporter Exportin-1 Attenuates Kidney Cancer Growth

(2014) Hiromi I. Wettersten et al.   PLoS One

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias

(2013) C. J. Walker et al.   BLOOD

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia

(2013) Julia Etchin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention

(2013) Irfana Muqbil et al.   CURRENT DRUG TARGETS

CRM1 and BRAF Inhibition Synergize and Induce Tumor Regression in BRAF-Mutant Melanoma

(2013) R. A. Salas Fragomeni et al.   MOLECULAR CANCER THERAPEUTICS

Post-translational modifications and the Warburg effect

(2013) T Hitosugi et al.   ONCOGENE

Choreography of importin- /CAS complex assembly and disassembly at nuclear pores

(2013) C. Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CRM1 Is a Cellular Target of Curcumin: New Insights for the Myriad of Biological Effects of an Ancient Spice

(2013) Mingshan Niu et al.   TRAFFIC

Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice

(2012) Asfar S. Azmi et al.   GASTROENTEROLOGY

The nucleoporin-like protein NLP1 (hCG1) promotes CRM1-dependent nuclear protein export

(2012) I. Waldmann et al.   JOURNAL OF CELL SCIENCE

CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity

(2011) K. Sakakibara et al.   BLOOD

Pancreatic cancer

(2011) Audrey Vincent et al.   LANCET

The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport

(2010) Jean-Yves Wach et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Pancreatic Cancer Stem Cells: Implications for the Treatment of Pancreatic Cancer

(2008) D. M. Simeone   CLINICAL CANCER RESEARCH